Companies: 10,795·Total market cap: $144.5T
Cingulate Inc.

Cingulate Inc.

CINGNASDAQHealthcare● Active
$4.88
+$0.35(+7.73%)
Market Cap$27358587
P/E Ratio
52W High$11.89
52W Low$3.16
Overview

Cingulate Inc. (CING) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

cing · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Cingulate Inc. (CING) measures how much investors pay for each dollar of the company's trailing earnings. CING's current PE ratio of N/A is calculated by dividing its stock price of $4.88 by its TTM earnings per share of -$5.10.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-1.32
Based on 5 analysts
EPS (TTM)
-$5.10
TTM · diluted EPS
PEG Ratio
0.02
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cingulate Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Cingulate Inc.
Cingulate Inc.You
CING
$27MN/A-$5.10
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc.
ALLR
$26MN/A-$0.78
BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp.
BCTX
$6MN/A-$19.37
CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc.
CASI
$2MN/A-$2.56
Clearside Biomedical, Inc.
Clearside Biomedical, Inc.
CLSD
$2MN/A-$6.98
Entero Therapeutics, Inc.
Entero Therapeutics, Inc.
ENTO
$14MN/A-$4.05
Kairos Pharma, Ltd.
Kairos Pharma, Ltd.
KAPA
$10MN/A-$0.30

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-4.13
2024-12-31
FY2024
$-4.34
2023-12-31
FY2023
$-10.40
2022-12-31
FY2022
$-12.50
2021-12-31
FY2021
$-14.65
2020-12-31
FY2020
$-5.08
2019-12-31
FY2019
$-8.17

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Cingulate Inc. (CING) measures how much investors pay for each dollar of the company's trailing earnings. CING's current PE ratio of N/A is calculated by dividing its stock price of $4.88 by its TTM earnings per share of -$5.10.

PE Ratio = Stock Price ÷ EPS (TTM)
= $4.88 ÷ -$5.10 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

CING pe ratio · 6 questions

CING's current PE ratio is N/A as of 2026-06-09, based on a stock price of $4.88 and TTM EPS of -$5.10. Data sourced from Financial Modeling Prep via CING's SEC 10-K and 10-Q filings.

CING PE ratioWhat is CING PE ratioCurrent PE ratio of CINGCING PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cingulate Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09